Avelumab and Merkel Cell Carcinoma: A Review of Biological Plausibility

From General Health Science to Occupational Exposure Concerns

The legacy context of general health and science information has long emphasized the interconnectedness of bodily systems and the importance of understanding how external factors influence overall well-being. This foundational perspective, rooted in holistic health principles, provides a valuable framework for examining emerging concerns in occupational settings. Within mass production environments, workers may encounter various substances that warrant careful evaluation of their potential health impacts. One such substance is Avelumab, a therapeutic agent used in oncology, which has raised questions regarding its possible association with Merkel Cell Carcinoma risk. Transitioning from a broad health awareness heritage to a focused occupational exposure concern, it becomes pertinent to consider the biological plausibility of such a relationship. This shift in perspective allows for a systematic inquiry into how Avelumab exposure, particularly in occupational contexts, might influence carcinogenic processes. The discussion now moves toward examining the specific pathways and mechanisms that could underlie this potential risk, without delving into disease-specific mechanistic claims, but rather maintaining a neutral academic tone that respects the legacy of general health science while addressing contemporary occupational health questions.

Biological Plausibility and Mechanistic Pathways

Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096). It is approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096; https://pubmed.ncbi.nlm.nih.gov/33439294). The approval was based on the JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096). However, the relationship between avelumab and MCC causation requires careful examination of biological plausibility, mechanistic pathways, and risk considerations. MCC has two primary etiologies: approximately 80% of cases are caused by the Merkel cell polyomavirus (MCPyV), while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385). Avelumab, as a PD-L1 inhibitor, works by blocking the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby enhancing the immune system's ability to recognize and attack cancer cells. This mechanism is the basis for its therapeutic use in MCC, where it has shown better overall response rates and longer duration of responses compared to conventional chemotherapy (https://pubmed.ncbi.nlm.nih.gov/34445385). However, immune checkpoint inhibitors like avelumab are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781). These irAEs can include a range of inflammatory conditions, but there is no established biological pathway by which avelumab directly causes the development of new MCC. Instead, the drug is used to treat existing MCC, and its mechanism is to inhibit PD-L1, not to induce oncogenesis. The reported adverse effects of avelumab are primarily immune-mediated, such as hypercalcaemia due to sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781), and not the initiation of MCC.

Causation-Related Considerations and Evidence

The concept of avelumab causing MCC is counterintuitive given its approved indication for treating the disease. In clinical practice, avelumab is administered to patients with established metastatic MCC, and its use is associated with response rates of up to 62% for PD-1/PD-L1 inhibitors in general (https://pubmed.ncbi.nlm.nih.gov/36450381). However, approximately 50% of patients do not respond to immune checkpoint inhibitors or develop irAEs due to mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385). For patients who are refractory to avelumab, alternative treatments like combined ipilimumab and nivolumab have been used, with some patients responding (https://pubmed.ncbi.nlm.nih.gov/33439294; https://pubmed.ncbi.nlm.nih.gov/36450381). This suggests that avelumab does not cause MCC but rather is a treatment that may fail in some patients, leading to disease progression. There is no evidence in the provided sources that avelumab induces MCC de novo; instead, the drug is used to manage the disease.

Timeline and Warning Adequacy

The timeline between avelumab exposure and harm is typically related to treatment failure or irAEs, not the development of new MCC. In the JAVELIN Merkel 200 trial, responses were observed in patients with chemotherapy-refractory disease, indicating that avelumab was given after MCC diagnosis (https://pubmed.ncbi.nlm.nih.gov/29799096). Immune-related adverse events, such as hypercalcaemia from sarcoidosis reactivation, can occur during treatment and are managed with corticosteroids, with avelumab therapy sometimes safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781). For patients who are refractory, the timeline from avelumab initiation to documented progression or lack of response is variable, but the harm is from the underlying disease, not from avelumab causing MCC. The literature does not support a causal link where avelumab exposure precedes the onset of MCC; rather, avelumab is administered after MCC diagnosis. The adequacy of warnings regarding avelumab and MCC is reflected in its approved labeling, which indicates its use for metastatic MCC. The drug's prescribing information includes warnings about immune-related adverse events, but there is no warning about avelumab causing MCC because the drug is indicated for its treatment. The evidence shows that avelumab is a therapeutic agent for MCC, not a causative factor. For affected patients, the primary risk is treatment failure or irAEs, not drug-induced carcinogenesis. The provided sources do not indicate any warnings about avelumab causing MCC, as this would contradict its approved indication. In summary, the biological plausibility of avelumab causing MCC is not supported by the evidence. Avelumab is an immune checkpoint inhibitor used to treat MCC, and its mechanism of action is to block PD-L1, not to induce cancer. The drug's adverse effects are immune-related, and the timeline of exposure is after MCC diagnosis. Warnings appropriately reflect its therapeutic use, and causation considerations focus on treatment outcomes rather than drug-induced disease.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Can Avelumab cause Merkel Cell Carcinoma?

No, there is no evidence that Avelumab causes Merkel Cell Carcinoma. Avelumab is an immune checkpoint inhibitor used to treat existing MCC, and its mechanism of action is to block PD-L1, not to induce cancer. The drug is administered after MCC diagnosis, and its adverse effects are immune-related, not carcinogenic.

What is the biological plausibility of Avelumab causing MCC?

The biological plausibility is not supported. Avelumab targets PD-L1 to enhance immune response against tumor cells. MCC is primarily caused by Merkel cell polyomavirus or UV-induced mutations. There is no established pathway by which Avelumab initiates new MCC; instead, it is used therapeutically for the disease.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.